Dicerna Pharmaceuticals (DRNA) Shares are Up 39.01%

Dicerna Pharmaceuticals (DRNA) : Traders are bullish on Dicerna Pharmaceuticals (DRNA) as it has outperformed the S&P 500 by a wide margin of 88.27% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 38.78%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 39.01% in the last 1 week, and is up 87.26% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 60.04% and the 50-Day Moving Average is 68.88%.The 200 Day SMA reached 15.26%


Dicerna Pharmaceuticals (NASDAQ:DRNA): After opening at $5.17, the stock dipped to an intraday low of $5.13 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.1 and the buying power remained strong till the end. The stock closed at $5.88 for the day, a gain of 13.08% for the day session. The total traded volume was 1,472,805. The stocks close on the previous trading day was $5.88.

Dicerna Pharmaceuticals (DRNA) : 4 Wall Street analysts covering Dicerna Pharmaceuticals (DRNA) believe that the average level the stock could reach for the short term is $13.38. The maximum price target given is $19 and the minimum target for short term is around $4, hence the standard deviation is calculated at $7.09.

Dicerna Pharmaceuticals, Inc. (Dicerna) is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNA interference (RNAi) technology platform to build a pipeline in these therapeutic areas. The Company is in collaboration with two companies for oncology development programs with the global pharmaceutical company Kyowa Hakko Kirin Co., Ltd. (KHK). Its current development programs include Dacryocystorhinostomy (DCR)-PH1 for Primary Hyperoxaluria Type 1 (PH1), Additional Liver Targets, DCR-MYC for MYC-related cancers and KRAS Program. Dicernas discovery approach is based on double-stranded RNA molecules, called Dicer Substrate siRNA (DsiRNA).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *